

## Letter to the Editor

**Cite this article:** Gokalp S, Çilsal E, Yukcu B, Yolcu C, Akkoc G, and Guzeltaş A (2021) Pericardial effusion secondary to COVID-19 infection. *Cardiology in the Young* **31**: 685. doi: [10.1017/S1047951121001359](https://doi.org/10.1017/S1047951121001359)







Received: 28 February 2021

Accepted: 5 March 2021

First published online: 8 April 2021

**Author for correspondence:**

Asst Prof S. Gokalp, Department of Pediatric Cardiology, University of Health Sciences, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul SBU Mehmet Akif Ersoy Gogus Kalp Damar Cerrahisi Hastanesi Turgut Ozal Bulvarı No: 11 34303 Kucukcekmece-Istanbul, Istanbul, Turkey.  
Tel: +533 5151474; Fax: +212 4719494,  
E-mail: [sgokalp@hotmail.com](mailto:sgokalp@hotmail.com)

Selman Gokalp<sup>1</sup> , Erman Çilsal<sup>2</sup> , Bekir Yukcu<sup>1</sup> , Canan Yolcu<sup>3</sup> ,  
Gulsen Akkoc<sup>4</sup>  and Alper Guzeltaş<sup>1</sup> 

<sup>1</sup>Department of Pediatric Cardiology, University of Health Sciences, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey; <sup>2</sup>Department of Pediatric Cardiology, Adana Numune Training and Research Hospital, Yuregir, Adana, Turkey; <sup>3</sup>Department of Pediatric Cardiology, University of Health Sciences, Istanbul Haseki Education and Research Hospital, Istanbul, Turkey and <sup>4</sup>Department of Pediatric Infectious Diseases, University of Health Sciences, Istanbul Haseki Education and Research Hospital, Istanbul, Turkey

Dear Editor,

We thank Mungmunpantip and Wiwanitkit for their interest in our manuscript “A case of a very large haemorrhagic pericardial effusion in an adolescent patient with COVID-19 infection.”. Authors claim that pericardial effusion in patients with COVID-19 is typically not a haemorrhagic effusion. Our knowledge about COVID-19 infection grows each day; we learn different clinical entities related to this infection. As shown by many other case reports published either previously or later than our manuscript, pericardial effusion secondary to COVID-19 infection might be either haemorrhagic<sup>1,2</sup> or serohaemorrhagic in nature.<sup>3–6</sup> Our patient’s platelet count was  $352 \times 10^9/L$ , coagulation studies revealed prothrombin time 14.4 s, activated partial thromboplastin time 22.3 s, an international normalised ratio of 1.23. Fibrinogen and D-dimer were 440 mg/dl and 1.81 µg/ml, respectively. If the patient has an underlying haemostatic disorder, he probably had an associated haemorrhage. Also, developing hemopericardium without any other bleeding problems would be an unexpected clinical finding. Since the patient had no mucocutaneous bleeding or other reasons to suspect a haemostasis disorder, we did not need a complete laboratory workup.

We appreciated their acknowledgement of tuberculosis as a possible cause of the pericardial effusion. Our manuscript has already mentioned that the patient’s BCG scar was positive, and the tuberculin skin test was negative. As a developing country, we consider tuberculosis infection in every patient with pneumonia or pleural effusion. The patients’ pericardial fluid tested negative for acid-fast bacilli smear, and culture for tuberculosis was negative.

The diagnosis of myopericarditis is usually based on laboratory tests confirming or excluding possible aetiologies and infections. In our case, after excluding all other possible causes and confirmatory laboratory tests for COVID-19, it should be logical to accept the pericardial effusion secondary to COVID-19 infection rather than a coincidence.

**Acknowledgements.** None.

**Financial support.** This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.

**Conflicts of interest.** None.

**Ethical approval.** All procedures performed in this case were in accordance with the ethical standards of the institutional and national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards.

**Informed consent.** Informed consent was obtained from the patient and the patients’ parents.

## References

1. Dabbagh MF, Aurora L, D’Souza P, et al. Cardiac tamponade secondary to COVID-19. *J Am Coll Cardiol Case Rep* 2020; **2**: 1326–1330.
2. Parsova KE, Pay L, Oflu Y, et al. A rare presentation of a patient with COVID-19: cardiac tamponade. *Turk Kardiyol Dern Ars* 2020; **48**: 703–706.
3. Sauer F, Dagrenat C, Couppie P, et al. Pericardial effusion in patients with COVID-19: case series. *Eur Heart J Case Rep* 2020; **4**(F11): 1–7.
4. Farina A, Uccello G, Spreafico M, et al. SARS-CoV-2 detection in the pericardial fluid of a patient with cardiac tamponade. *Eur J Intern Med* 2020; **76**: 100–101.
5. Ejikeme C, Gonzalez M, Elkattawy S, et al. Subacute COVID-19 infection presenting as indolent large pericardial effusion. *Cureus* 2020; **12**: e10769.
6. Amoozgar B, Kaushal V, Mubashar U, et al. Symptomatic pericardial effusion in the setting of asymptomatic COVID-19 infection: a case report. *Medicine* 2020; **99**: e22093.